1. Home
  2. ONTX

ONTX

Onconova Therapeutics Inc.

Logo Onconova Therapeutics Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-12-2024 3:58pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
-
.
-
-
%

Onconova Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova's novel, proprietary multi-kinase inhibitor ON 123300 is currently in a dose-escalation and expansion Phase 1 trial in China, and an IND has been filed in the U.S. Its product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with KRAS+ lung adenocarcinoma in combination with nivolumab.

Founded: 1998 Country:
United States
United States
Employees: N/A City: NEWTOWN
Market Cap: 18.2M IPO Year: 2013
Target Price: $11.00 AVG Volume (30 days): 95.5K
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.90 EPS Growth: N/A
52 Week Low/High: $0.55 - $1.45 Next Earning Date: 05-13-2024
Revenue: $226,000 Revenue Growth: N/A
Revenue Growth (this year): -2.82% Revenue Growth (next year): 20.74%

Share on Social Networks: